Abstract: Methods and compositions are provided for covalently linking a chemical species to a recombinant or synthetic polypeptide. The methods involve the reaction of a thioester-comprising polypeptide with a reagent comprising a reactive amino-thiol group connected to the chemical species which is to be covalently linked to the polypeptide, via a linker. Such chemical species can be a functional group, a label or tag molecule, a biological molecule, a ligand, or a solid support. Efficient and catalyst-free methods for C-terminal protein labeling are also provided. The methods expand current capabilities in the area of protein functionalization, providing useful and complementary tools for the isolation, detection, characterization, and analysis of proteins in a variety of in vitro and in vivo applications.

Abstract: The present invention relates to the use for affinity purification of an antibody or a fragment of an antibody, of a ligand-substituted matrix comprising a support material and at least one ligand covalently bonded to the support material.

Abstract: The invention relates to a process for solution-phase synthesis of D-Arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide, an active ingredient used for both common and rare diseases including a mitochondrial targeted therapy for ischemia reperfusion injury.

Abstract: The present invention discloses structurally constrained synthetic peptides that have been optimized for the formation of a beta hairpin structure. Said peptides are able to inhibit or attenuate Dengue virus (DENV) infections. The invention also discloses pharmaceutical compositions containing these synthetic peptides, which are useful for the prevention and/or treatment of DENV-caused infections. Likewise, the invention disclosed a method for treating infections caused by this virus.

Abstract: The total synthesis and evaluation of key analogs of vancomycin containing single atom changes in the binding pocket are disclosed as well as their peripherally modified, N-(hydrophobe-substituted) derivatives exemplified by a N-4-(4?-chlorob-phenyl)-methyl derivative and their pharmaceutically acceptable salts are disclosed. Their evaluation indicates the combined pocket and peripherally modified analogs exhibit a remarkable spectrum of antimicrobial activity and truly impressive potencies against both vancomycin-sensitive and -resistant bacteria, and likely benefit from two independent and synergistic mechanisms of action. A pharmaceutical composition containing a contemplated compound or its pharmaceutically acceptable salt is disclosed, as is a method of treating a bacterial infection in a mammal by administering an antibacterial amount of a contemplated compound or its salt as above to an infected mammal in need of treatment.

Abstract: The invention provides polypeptides interacting with the binding of the RSV phosphoprotein P with the RSV nucleoprotein N and methods of using such polypeptides in the treatment and/or prevention of RSV infection.

Abstract: A recombinant cytotoxin is provided. The recombinant cytotoxin of the present invention comprises a cytotoxin, a cell penetrating peptide (CPP), and Asp-Glu-Val-Asp (DEVD) sequence inserted in the cytotoxin. The recombinant cytotoxin can induce a targeting cell into the apoptotic pathway and be cleaved by the enzyme generated from apoptotic pathway. The present invention also provides a method for treating cancer, comprising administrating the recombinant cytotoxin to a subject.

Abstract: Method for preparing a protein isolate of the biomass of microalgae of the genus Chlorella, includes: supplying a microalgal biomass produced by fermentation; optionally washing the biomass so as to eliminate soluble interstitial compounds, thermal permeabilization of the biomass at a temperature between 50 and 150° C.

Abstract: As a calcium indicator protein having an excellent fluorescent characteristic and calcium reactivity, there is provided DNA in which one of a nucleotide sequence derivative of a calmodulin-binding sequence (ckkap sequence) of calcium/calmodulin-dependent protein kinase kinase and a nucleotide sequence encoding a calcium-binding sequence (CaM sequence) of calmodulin is linked to a 5? end of a nucleotide sequence encoding a fluorescent protein, and the other nucleotide sequence is linked to a 3? end of the nucleotide sequence encoding the fluorescent protein. The calcium indicator protein encoded by this DNA, which based on the derivative of the ckkap sequence as a binding domain for the calcium-bound CaM sequence, exhibits a fluorescent characteristic and calcium reactivity superior to those of conventional calcium indicator proteins.

Abstract: Recombinant polypeptides and compositions as described herein and are useful in methods to promote epidermal tissue regeneration and/or to promote wound healing in a variety of tissues subject in need thereof. The method comprises administering to a tissue or wound in need thereof an effective amount of a recombinant polypeptide operatively linked to a carrier protein or a composition containing the recombinant polypeptide linked to a carrier protein.

Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor under the control of an inducible promoter. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain under the control of a drug inducible promoter. Controlling the expression of the chimeric receptor provides for the ability to turn expression on and off depending on the status of the patient.

Abstract: The present invention relates to the purification of TNFR:Fc fusion protein. More specifically related to process of purification of TNFR:Fc fusion protein wherein the HCP is reduced. The present invention is directed to the use of mixed-mode chromatography and/or affinity chromatography to produce TNFR:Fc fusion protein which is substantially free of at least one of the protein degrading enzyme present in HCP.

Abstract: Provided are wild-type, S252W mutant-type, and P253R mutant-type FGFR2b extracellular segments and truncated proteins thereof, coding genes of the foregoing proteins, a recombinant vector comprising the genes, a host cell, a method for preparing the proteins, and a fusion protein of the proteins and an Fc segment. Also provided are applications of the proteins and a composition comprising the proteins in treating eczema, acne, psoriasis, skin allergy, seborrheic dermatitis, or seborrheic alopecia.

Abstract: The present invention provides a modified polypeptide which binds Factor VIII. The modified polypeptide comprises a sequence as shown in SEQ ID NO:3 in which the sequence comprises at least a modification at position 1 or 3 such that the modified polypeptide binds to Factor VIII with an off rate at least 5 fold lower than a reference polypeptide comprising an unmodified SEQ ID NO:3.

Abstract: The disclosure describes methods of making high-strength NDGA collagen and associated methods of preparing collagen preparatory material and medical bioprostheses.

Abstract: The present invention relates to a fusion protein comprising a protein transduction domain capable of introducing the fusion protein into a mammalian cell and an anti-apoptotic protein comprising the amino acid of the sequence of SEQ ID NO:1 or an anti-apoptotically active variant or fragment thereof. The invention also relates to a pharmaceutical composition comprising such a fusion protein, in particular for blocking apoptosis in a patient in need thereof. The invention also provides a polynucleotide encoding such a fusion protein, an expression vector comprising the polynucleotide and a host cell comprising the expression vector. In a further aspect, the invention relates to the use of any of theses materials for the preparation of a medicament for blocking apoptosis in a patient in need thereof.

Abstract: Disclosed are the methods of curing HBV infection and providing complete protection against HBV infection in a simplified HBV immunization schedule. The mechanistic basis for curing HBV infection is founded on the understanding that hepatitis B virus infection is established and prolonged by new rounds of infection with continuously produced viruses, which are not fully neutralized because of insufficient endogenous neutralizing antibodies. The methods of curing HBV infection including chronic HBV infection are aimed to block new rounds of HBV infection. The guidelines for establishing treatment regimens for curing HBV infection, include production or administration of sufficient level of HBV neutralizing antibodies in treated patients.

Abstract: Described is an anti-HSV antibody or an antigen-binding fragment thereof for use in treating an acute infection of mucosal or epidermal tissue in a subject caused by HSV-1 or HSV-2 selected from the group consisting of Herpes simplex labialis, Herpes simplex genitalis, chronic or disseminated cutaneous herpes simplex infection, Herpes gladiatorum and Eczema herpeticum, wherein said antibody is to be topically administered as well as to a pharmaceutical composition comprising an effective amount of said antibody or antigen-binding fragment thereof and at least one pharmaceutically acceptable excipient.

Abstract: The present disclosure relates to camel id antibodies that inhibit growth, and colonization of Salmonella serovars. The present disclosure also relates to a modified Lactobacillus as a delivery vehicle for controlling salmonella in a host organism.

Abstract: The present invention relates to the provision of single chain variable fragment (scFv) elongation mutants. In addition, the present invention relates to a pharmaceutical composition comprising said scFv elongation mutants, as well as a nucleotide sequence encoding said scFv elongation mutants, a vector comprising said nucleotide sequence or a host cell expressing said nucleotide sequence. Particular embodiments relate to elongation mutants of the scFv-h3D6 which is derived from monoclonal antibody mAb-h3D6 (bapineuzumab). It is further disclosed a method of prevention or treatment of a patient in risk of suffering, or already diagnosted as suffering, Alzheimer disease that comprises the administration to said patient of an effective amount of the scFv elongation mutants of scFv-h3D6.

Abstract: The disclosure relates to antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The disclosure also relates to diagnostic, prophylactic and therapeutic methods using anti-tau antibodies.

Abstract: Provided are novel TDP-43-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.

Abstract: The present disclosure relates generally to anti-C1q antibody Fab fragments and methods of using the same.

Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).

Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.

Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanising antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.

Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.

Abstract: Methods that involve detection of a DSG3 protein for diagnosing cancer are disclosed. In lung cancer, the expression of DSG3 was found to be enhanced at very high frequency at the gene level and protein level. Methods of the present invention can be carried out using an antibody that recognizes a DSG3 protein. Pharmaceutical compositions, cell growth inhibitors, and anticancer agents containing a DSG3-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in DSG3-expressing cells and methods of suppressing proliferation of DSG3-expressing cells by contacting the DSG3-expressing cells with DSG3-binding antibodies are also disclosed.

Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser9lPhe substitution in the hA19 VH sequence.

Abstract: A targeted T-cell engaging agent for treating a condition characterized by the presence of unwanted cells includes (a) a targeting moiety that is capable of targeting the unwanted cells; (b) a first T-cell engaging domain capable of T-cell engaging activity when binding a second T-cell engaging domain, wherein the second T-cell engaging domain is not part of the agent; (c) at least one inert binding partner capable of binding to the first T-cell engaging domain such that the first T-cell engaging domain does not bind to the second T-cell engaging domain unless the inert binding partner is removed; and (d) at least one cleavage site separating the first T-cell engaging domain and the inert binding partner, wherein the cleavage site is: (i) cleaved by an enzyme expressed by the unwanted cells; (ii) cleaved through a pH-sensitive cleavage reaction inside the unwanted cell; (iii) cleaved by a complement-dependent cleavage reaction; or (iv) cleaved by a protease that is colocalized to the unwanted cell by a target

Abstract: A method of modulating immunity in a mammal is provided by modulating Galectin-9 activity in the mammal. Promoting or enhancing immunity may be effected by activating or stimulating Galectin-9 activity in the mammal, such as by administering a Galectin-9 agonist to the mammal. The agonist may be multimeric, soluble PD-L2 or an agonist antibody that binds Galectin-9. Suppressing or preventing immunity may be achieved by inhibiting or blocking Galectin-9 activity in the mammal, such as by administering an antagonist antibody or antibody fragment that binds Galectin-9 or that prevents or inhibits PD-L2 multimerisation and/or binding to Galectin-9. The aforementioned methods may be suitable for preventing or treating a disease, disorder or condition responsive to modulation of Galectin-9 activity. Also provided is a method of designing, screening, engineering or otherwise producing a Galectin-9 agonist, inhibitor or antagonist that may be useful for modulating immunity by modulating Galectin-9 activity.

Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.

Abstract: The present invention relates to the characterization and production of biosimilars.

Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis.

Abstract: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3R?) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3R?-expressing cell population, the methods comprising contacting a population of IL3R?-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3R?. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3R? chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3R?-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3R?.

Abstract: The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.

Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of:—a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and,—a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.

Abstract: A process for preparing an ABS graft copolymer, which comprises a step for isolating the graft copolymer B present in an aqueous dispersion by means of a precipitant which is an aqueous solution of a mixture of MgSO4, Al2(SO4) and/or H2SO4, is described. The ABS molding compositions obtained have an improved yellowness index and high surface gloss.

Abstract: Provided herein are organic solvent-based processes for the removal of rubber from non-Hevea plants such as TKS. By the use of the processes, solid purified rubber can be obtained that contains 0.05-0.5 weight % dirt, 0.2-1.5 weight % ash, and 0.1-4 weight % resin (when it has been dried so as to contain 0.8 weight % volatile matter).

Abstract: A system and method for a polyolefin reactor temperature control system having a first reactor temperature control path, a second reactor temperature control path, and a shared temperature control path. The shared temperature control path is configured to combine and process coolant return streams, and to provide coolant supply for the first reactor temperature control path and the second reactor temperature control path.

Abstract: A system and method for startup of a polyolefin reactor temperature control system having a first reactor temperature control path, a second reactor temperature control path, and a shared temperature control path. In some embodiments, during startup the second reactor temperature control path is configured to allow the temperature of a second reactor to rise due to the heat of the exothermic polymerization reaction occurring within reactor until reaching a predetermined setpoint temperature. In other embodiments, during startup a first reactor temperature control path is configured to include a heat exchanger used as a cooler, and a second reactor temperature control path is configured to include a heat exchanger used as a heater, to raise the temperature of the second reactor until reaching a predetermined setpoint temperature.

Abstract: In the high pressure polymerization of ethylene homopolymers or copolymers, conditions in the high pressure recycle system may lead to the build-up of low molecular weight oligomers and waxes. Sequentially draining knock-out pots, located downstream of a high pressure separator, at regular intervals can reduce the build-up of low molecular weight oligomers and waxes during the high pressure polymerization of alpha olefins.

Abstract: The present invention relates to a process for preparing ultra-high molecular weight polyalphaolefin. The process consists of polymerizing alphaolefin monomers using the catalyst system consisting of supported Ziegler-Natta catalyst without internal donor in presence of co-catalyst based on alkyl aluminums. The resulting ultra-high molecular weight polyalphaolefins having intrinsic viscosity ?10 dL/g are used as drag reducing polymers for increasing throughput in the pipelines by reducing frictional resistance in turbulent flow.

Abstract: Provided are a curable composition including an amide compound that is represented by Formula (1) below and of which a density of sulfonic acid is 3.9 milliequivalent/g or greater, a functional polymer hardened product, a stack or a device including a functional polymer membrane, an amide compound, and a manufacturing method thereof. m represents an integer of 1 or greater, n represents an integer of 2 or greater, L1 represents a m+1-valent linking group, and L2 represents an n-valent linking group. R1 represents a hydrogen atom or an alkyl group, and R2 represents —SO3?M+ or —SO3R3 (R3 represents an alkyl group or an aryl group). Here, in a case where there are plural R2's, not all of the R2's are —SO3R3. M+ represents a hydrogen ion, an inorganic ion, or an organic ion.

Abstract: To provide a fluorinated elastomer from which it is possible to produce a crosslinked article excellent in cold resistance and excellent in mechanical strength; a fluorinated elastomer composition containing said elastomer; and a fluorinated elastomer crosslinked article obtained by molding and crosslinking said composition. The fluorinated elastomer comprises units (A) based on vinylidene fluoride and units (B) based on a perfluorovinyl ether represented by CF2?CF—O—Rf, and has iodine atoms at main chain terminals, wherein the molar ratio [(A)/(B)] of units (A) to units (B) is from 88/12 to 50/50. In the formula, Rf is a C1-20 perfluoroalkyl group having a branched structure, or a C2-20 perfluoroalkyl group having a branched structure and also having an etheric oxygen atom between carbon atoms.

Abstract: The present application relates to novel copolymers and processes for the preparation thereof, where the copolymers comprise, as building blocks: a C1-20-alkyl (meth)acrylate and/or C8-20-vinylaromatics (monomer a); a monoethylenically unsaturated, hydrophilic monomer comprising at least one sulfonic acid group (—SO3M) (monomer b); and a monoethylenically unsaturated monomer comprising at least one oxazoline group (monomer c); and where the fraction of the monomers a) and b) is in total less than 50% by weight, based on the total amount of the monomers in the copolymer A.

Abstract: Provided herein are polymeric compositions having a relaxation time that is a function of pH. The polymeric compositions can include an anionic monomer, a cationic monomer, and a crosslinker. The crosslinker may comprise at least one of a diacrylate crosslinker and a dimethacrylate crosslinker. Also provided herein are methods of pH sensing, and methods of forming a polymeric composition. Kits of parts also are provided that include a polymeric composition. The polymeric compositions may be used to determine the pH of one or more biological tissues and/or liquids.

Abstract: The invention relates to highly biocompatible or biophilic un-cross-linked or cross-linked polymers comprising one or more side-chain active acrylic amino acids of formula I. The invention further concerns various highly biocompatible, cross-linked co-polymers comprising one or more monomers of formula I, and one or more other polymerizable monomers. Uses of such polymers and co-polymers for the production of contact lenses, intraocular lenses, implants, wound healing slabs, additives for food and cosmetics, conductive plastics, spinnable fibers, and the like are disclosed.

Abstract: A method of synthesizing a polynucleotide composition includes attaching a compound including at least one initiator or at least one transfer agent for a reversible deactivation radical polymerization to an end of a nucleotide chain assembly immobilized upon a solid phase support during a solid phase synthesis of a polynucleotide so that the initiator or the transfer agent is attacked to the end of a nucleotide chain assembly in a manner which is stable under conditions of deprotection of the polynucleotide, and growing a polymer from the initiator of from a site of the chain transfer agent via the reversible deactivation radical polymerization to form the polynucleotide composition.